Clinical Trials
320 trialsLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
PLANE-PC
University of Michigan Rogel Cancer Center
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
ALPINE 2
Technische Universität Dresden
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
NePenThe
Istituti Clinici Scientifici Maugeri SpA
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
LCNEC-ALPINE
Technische Universität Dresden
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
DeLLight
Asan Medical Center
STRAP
National Cancer Centre, Singapore
I-MAT
Melanoma and Skin Cancer Trials Limited
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Cabozantinib in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
SUR-CAN
Centre Oscar Lambret
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Fezo-ADT
Brigham and Women's Hospital
A Study of Pasireotide in People With Prolactinoma
Memorial Sloan Kettering Cancer Center
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
LAMPARA
Columbia University
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Shanghai Chest Hospital
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington